AstraZeneca PLC (NASDAQ:AZN) Q1 2021 Earnings Conference Call April 30, 2021 6:45 AM ET Company Participants Pascal Soriot - ED and CEO Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, Biopharmaceuticals Business Unit Marc Dunoyer - ED and CFO Mene Pangalos - EVP, Biopharmaceuticals R&D Susan Galbraith - Oncology R&D Cristian Massacesi - SVP, Late-Stage Oncology R&D Leon Wang - EVP, International and China President Conference Call Participants Peter Welford - Jefferies Tim Anderson - Wolfe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2020 Earnings Conference Call February 11, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - Executive Vice President, Oncology Business Unit Ruud Dobber - Executive Vice President, Biopharmaceuticals Business Unit Marc Dunoyer - Executive Director and Chief Financial Officer Mene Pangalos - Executive Vice President, Biopharmaceuticals R&D Pam Cheng - Executive Vice President, Operations and IT Leon Wang - E ...

AstraZeneca PLC (NASDAQ:AZN) Q3 2020 Earnings Conference Call November 5, 2020 6:45 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President of the Oncology Business Unit Ruud Dobber – Executive Vice President of the Biopharmaceuticals Business Unit Marc Dunoyer – Executive Director and Chief Financial Officer Mene Pangalos – Executive Vice President of the Biopharmaceuticals R&D Group Jose Baselga – Executive Vice President of Oncology R&D Pam Cheng – E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...